Application of valsartan in glomerulonephritis patients

AIM:To observe the effect of valsartan for the treatment of proteinuria, hypertension and parameters of renal function in glomerulonephritis patients. METHODS: Seventy patients with glomerulonephritis were randomly divided into two groups. Valsartan group( n =36) received valsartan 80-160 mg, po ,qd for 8 wk, and benazepril group( n =34) received benazepril 10 mg, po ,qd for 8 wk. RESULTS: There was significant improvement in hypertension and proteinuria after valsartan and benazepril therepy( P 0.05),the clinical effective rates were similar,the decrease of the systolic and diastolic blood pressure were (3.7±1.0)kPa/(1.9±0.9) kPa and (3.8±1.2) kPa /(1.8±1.0) kPa separately after 4 wk.After treatment the decrease of urinary protein excretion were (0.42±0.28) g·24 h -1 and (0.4±0.3)g·24 h -1 separately. While no marked differences occur between valsartan group and benazepril group( P 0.05). Serum levels of creatinine and BUN were not increased in valsartan and benazepril groups. CONCLUSION: Valsartan oral therapy proved to be good to glomerulonephritis patients.